Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Publikationen

Suchbegriffe: ANTIBODIES, MONOCLONAL - THERAPEUTIC USE , . Treffer: 110

2017

Descamps, OS; Fraass, U; Dent, R; März, W; Gouni-Berthold, I Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.
Int J Clin Pract. 2017; 71(8): Doi: 10.1111/ijcp.12979 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Fasching, P; Stradner, M; Graninger, W; Dejaco, C; Fessler, J Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.
Molecules. 2017; 22(1): Doi: 10.3390/molecules22010134 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Kolbinger, F; Loesche, C; Valentin, MA; Jiang, X; Cheng, Y; Jarvis, P; Peters, T; Calonder, C; Bruin, G; Polus, F; Aigner, B; Lee, DM; Bodenlenz, M; Sinner, F; Pieber, TR; Patel, DD β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
J Allergy Clin Immunol. 2017; 139(3):923-932 Doi: 10.1016/j.jaci.2016.06.038 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Sliwa, T; Beham-Schmid, C; Burgstaller, S; Buxhofer-Ausch, V; Gastl, G; Geissler, K; Krauth, M; Krippl, P; Lang, A; Petzer, A; Wöhrer, S; Wölfler, A; Gisslinger, H Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.
Wien Klin Wochenschr. 2017; 129(9-10):293-302 Doi: 10.1007/s00508-016-1120-8 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2016

Bonin, S; Donada, M; Bussolati, G; Nardon, E; Annaratone, L; Pichler, M; Chiaravalli, AM; Capella, C; Hoefler, G; Stanta, G A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
Tumour Biol. 2016; 37(6):7295-7303 Doi: 10.1007/s13277-015-4543-3
Web of Science PubMed FullText FullText_MUG

Gouni-Berthold, I; Descamps, OS; Fraass, U; Hartfield, E; Allcott, K; Dent, R; März, W Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.
Br J Clin Pharmacol. 2016; 82(6):1412-1443 Doi: 10.1111/bcp.13066 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

März, W; Scharnagl, H; Gouni-Berthold, I; Silbernagel, G; Dressel, A; Grammer, TB; Landmesser, U; Dieplinger, H; Windler, E; Laufs, U LDL-Cholesterol: Standards of Treatment 2016: A German Perspective.
Am J Cardiovasc Drugs. 2016; 16(5):323-336 Doi: 10.1007/s40256-016-0179-y [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Narula, N; Kainz, S; Petritsch, W; Haas, T; Feichtenschlager, T; Novacek, G; Eser, A; Vogelsang, H; Reinisch, W; Papay, P The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
Aliment Pharmacol Ther. 2016; 44(2):170-80 Doi: 10.1111/apt.13671 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2015

de Ridder, L; Waterman, M; Turner, D; Bronsky, J; Hauer, AC; Dias, JA; Strisciuglio, C; Ruemmele, FM; Levine, A; Lionetti, P; ESPGHAN Paediatric IBD Porto Group Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group.
J Pediatr Gastroenterol Nutr. 2015; 61(4):503-508 Doi: 10.1097/MPG.0000000000000903 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Robert, C; Schachter, J; Long, GV; Arance, A; Grob, JJ; Mortier, L; Daud, A; Carlino, MS; McNeil, C; Lotem, M; Larkin, J; Lorigan, P; Neyns, B; Blank, CU; Hamid, O; Mateus, C; Shapira-Frommer, R; Kosh, M; Zhou, H; Ibrahim, N; Ebbinghaus, S; Ribas, A; KEYNOTE-006 investigators Pembrolizumab versus Ipilimumab in Advanced Melanoma.
N Engl J Med. 2015; 372(26):2521-2532 Doi: 10.1056/NEJMoa1503093 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Skrabl-Baumgartner, A; Weger, W; Salmhofer, W; Jahnel, J Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment.
Pediatr Dermatol. 2015; 32(1):e13-e14 Doi: 10.1111/pde.12457 (- Case Report)
Web of Science PubMed FullText FullText_MUG

2014

Marsche, G; Holzer, M; Wolf, P Antipsoriatic treatment extends beyond the skin: recovering of high-density lipoprotein function.
Exp Dermatol. 2014; 23(10):701-704 Doi: 10.1111/exd.12483 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Pichler, M; Winter, E; Ress, AL; Bauernhofer, T; Gerger, A; Kiesslich, T; Lax, S; Samonigg, H; Hoefler, G miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
J Clin Pathol. 2014; 67(3):198-203 Doi: 10.1136/jclinpath-2013-201904
Web of Science PubMed FullText FullText_MUG

2013

Klein, K; Süsal, C; Schäfer, SM; Becker, LE; Beimler, J; Schwenger, V; Zeier, M; Schemmer, P; Macher-Goeppinger, S; Scherer, S; Opelz, G; Morath, C Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
Atheroscler Suppl. 2013; 14(1):199-202 Doi: 10.1016/j.atherosclerosissup.2012.10.030
Web of Science PubMed FullText FullText_MUG

Pyxaras, SA; Mangiacapra, F; Verhamme, K; Di Serafino, L; De Vroey, F; Toth, G; Perkan, A; Salvi, A; Bartunek, J; De Bruyne, B; Wijns, W; Sinagra, G; Barbato, E Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention.
Catheter Cardiovasc Interv. 2013; 82(4):604-611 Doi: 10.1002/ccd.24837
Web of Science PubMed FullText FullText_MUG

Ramsey, H; Pilat, N; Hock, K; Klaus, C; Unger, L; Schwarz, C; Baranyi, U; Gattringer, M; Schwaiger, E; Wrba, F; Wekerle, T Anti-LFA-1 or rapamycin overcome costimulation blockade-resistant rejection in sensitized bone marrow recipients.
Transpl Int. 2013; 26(2):206-218 Doi: 10.1111/tri.12021 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Scholz, CW; Pinto, A; Linkesch, W; Lindén, O; Viardot, A; Keller, U; Hess, G; Lastoria, S; Lerch, K; Frigeri, F; Arcamone, M; Stroux, A; Frericks, B; Pott, C; Pezzutto, A 90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.
J Clin Oncol. 2013; 31(3):308-313 Doi: 10.1200/JCO.2011.41.1553 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2012

Brunasso, AM; Puntoni, M; Massone, C Drug survival rates of biologic treatments in patients with psoriasis vulgaris.
Br J Dermatol. 2012; 166(2):447-449 Doi: 10.1111/j.1365-2133.2011.10557.x
Web of Science PubMed FullText FullText_MUG

Gutzmer, R; Wollenberg, A; Ugurel, S; Homey, B; Ganser, A; Kapp, A Cutaneous side effects of new antitumor drugs: clinical features and management.
Dtsch Arztebl Int. 2012; 109(8):133-140 Doi: 10.3238/arztebl.2012.0133 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Inzinger, M; Weger, W; Salmhofer, W; Wolf, P Differential Response of Chronic Plaque Psoriasis to Briakinumab vs. Ustekinumab.
Acta Derm Venereol. 2012; 92(4):357-358 Doi: 10.2340/00015555-1243 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Pichler, M; Winter, E; Stotz, M; Eberhard, K; Samonigg, H; Lax, S; Hoefler, G; Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer.
Br J Cancer. 2012; 106(11):1826-1832 Doi: 10.1038/bjc.2012.175 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Salmhofer, W; Case presentation of moderate-severe psoriasis.
J Eur Acad Dermatol Venereol. 2012; 26 Suppl 5(10):19-20 Doi: 10.1111/j.1468-3083.2012.04607.x (- Case Report)
Web of Science PubMed FullText FullText_MUG

Valentin, T; Neumeister, P; Pichler, M; Rohn, A; Koidl, C; Haas, D; Heiling, B; Asslaber, M; Zollner-Schwetz, I; Hoenigl, M; Salzer, HJ; Krause, R; Buzina, W Disseminated Geosmithia argillacea infection in a patient with gastrointestinal GvHD.
Bone Marrow Transplant. 2012; 47(5): 734-736. Doi: 10.1038/bmt.2011.149 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2011

Brunasso, AM; Massone, C Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: An update on infliximab.
Acta Derm Venereol. 2011; 91(1):70-71 Doi: 10.2340/00015555-0989 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Brunasso, AM; Puntoni, M; Delfino, C; Massone, C Different response rates between palmoplantar involvement and diffuse plaque psoriasis in patients treated with infliximab.
Eur J Dermatol. 2011; 22(1):133-135 Doi: 10.1684/ejd.2011.1567 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Brunasso, AM; Puntoni, M; Gulia, A; Massone, C Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review.
Rheumatology (Oxford). 2011; 50(9):1700-1711 Doi: 10.1093/rheumatology/ker190 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Brunasso, AM; Puntoni, M; Salvini, C; Delfino, C; Curcic, P; Gulia, A; Massone, C Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients.
Acta Derm Venereol. 2011; 91(1):44-49 Doi: 10.2340/00015555-0959 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Eschenhagen, T; Force, T; Ewer, MS; de Keulenaer, GW; Suter, TM; Anker, SD; Avkiran, M; de Azambuja, E; Balligand, JL; Brutsaert, DL; Condorelli, G; Hansen, A; Heymans, S; Hill, JA; Hirsch, E; Hilfiker-Kleiner, D; Janssens, S; de Jong, S; Neubauer, G; Pieske, B; Ponikowski, P; Pirmohamed, M; Rauchhaus, M; Sawyer, D; Sugden, PH; Wojta, J; Zannad, F; Shah, AM Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
EUR J HEART FAIL. 2011; 13(1): 1-10. Doi: 10.1093/eurjhf/hfq213 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

Hautmann, AH; Elad, S; Lawitschka, A; Greinix, H; Bertz, H; Halter, J; Faraci, M; Hofbauer, LC; Lee, S; Wolff, D; Holler, E Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease.
Transpl Int. 2011; 24(9):867-879 Doi: 10.1111/j.1432-2277.2011.01264.x [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Hohloch, K; Delaloye, AB; Windemuth-Kieselbach, C; Gómez-Codina, J; Linkesch, W; Jurczak, W; Cacchione, R; Suh, C; Zinzani, PL; Trümper, L Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the international radioimmunotherapy network.
J Nucl Med. 2011; 52(9):1354-1360 Doi: 10.2967/jnumed.111.089920 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Hohloch, K; Zinzani, PL; Linkesch, W; Jurczak, W; Deptala, A; Lorsbach, M; Windemuth-Kiesselbach, C; Wulf, GG; Truemper, LH Radioimmunotherapy with (90)Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network.
Bone Marrow Transplant. 2011; 46(6): 901-903. Doi: 10.1038/bmt.2010.202 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Inzinger, M; Heschl, B; Weger, W; Hofer, A; Legat, FJ; Gruber-Wackernagel, A; Tilz, H; Salmhofer, W; Quehenberger, F; Wolf, P Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
Br J Dermatol. 2011; 165(3):640-645 Doi: 10.1111/j.1365-2133.2011.10396.x
Web of Science PubMed FullText FullText_MUG Google Scholar

Reinisch, W; Dejaco, C; Feichtenschlager, T; Haas, T; Kaser, A; Miehsler, W; Novacek, G; Petritsch, W; Platzer, R; Tilg, H; Vogelsang, H; Knoflach, P; Arbeitsgruppe Chronisch-entzündliche Darmerkrankungen der ÖGGH Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology].
Z Gastroenterol. 2011; 49(4):534-542 Doi: 10.1055/s-0029-1245930
Web of Science PubMed FullText FullText_MUG

Resch, B; Paes, B Are late preterm infants as susceptible to RSV infection as full term infants?
EARLY HUM DEV. 2011; 87(2): S47-S49. Doi: 10.1016/j.earlhumdev.2011.01.010
Web of Science PubMed FullText FullText_MUG

Weger, W An update on the diagnosis and management of psoriatic arthritis.
G Ital Dermatol Venereol. 2011; 146(1): 1-8.
Web of Science PubMed

2010

Brunasso, AM; Massone, C Rotational therapy with TNF-alpha blockers for recalcitrant hidradenitis suppurativa.
Eur J Dermatol. 2010; 20(5):644-646 Doi: 10.1684/ejd.2010.1037 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Brunasso, AM; Scocco, GL; Massone, C Dermatomyositis during adalimumab therapy for rheumatoid arthritis.
J Rheumatol. 2010; 37(7):1549-1550 Doi: 10.3899/jrheum.091413 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Carbonell-Estrany, X; Simões, EA; Dagan, R; Hall, CB; Harris, B; Hultquist, M; Connor, EM; Losonsky, GA; Motavizumab Study Group Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.
Pediatrics. 2010; 125(1):e35-e51 Doi: 10.1542/peds.2008-1036 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Chowers, Y; Sturm, A; Sans, M; Papadakis, K; Gazouli, M; Harbord, M; Jahnel, J; Mantzaris, GJ; Meier, J; Mottet, C; Peyrin-Biroulet, L; Allez, M Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists.
J Crohns Colitis. 2010; 4(4):367-376 Doi: 10.1016/j.crohns.2010.05.011 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Dejaco, C; Duftner, C; Klotz, W; Schirmer, M; Herold, M Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis.
Rheumatol Int. 2010; 30(4):451-454 Doi: 10.1007/s00296-009-0978-4
Web of Science PubMed FullText FullText_MUG

El Shabrawi-Caelen, L; La Placa, M; Vincenzi, C; Haidn, T; Muellegger, R; Tosti, A Adalimumab-induced psoriasis of the scalp with diffuse alopecia: A severe potentially irreversible cutaneous side effect of TNF-alpha blockers.
Inflamm Bowel Dis. 2010; 16(2):182-183 Doi: 10.1002/ibd.20954 (- Case Report)
Web of Science PubMed FullText FullText_MUG

Hermann, J Spondyloarthritis and quality of life.
Z RHEUMATOL. 2010; 69(3): 213-219. Doi: 10.1007/s00393-009-0572-x
Web of Science PubMed FullText FullText_MUG

Köse, O; Zimmerhackl, LB; Jungraithmayr, T; Mache, C; Nürnberger, J New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
Semin Thromb Hemost. 2010; 36(6):669-672 Doi: 10.1055/s-0030-1262889 (- Case Report)
Web of Science PubMed FullText FullText_MUG